Explore our core product offerings manufactured under strict international regulatory compliance.
An authoritative analysis of Bruton’s Tyrosine Kinase (BTK) inhibitor market growth, regulatory frameworks, and CDMO opportunities.
Ibrutinib (CAS Number: 936563-96-1), a first-in-class, small-molecule, targeted oral Bruton’s Tyrosine Kinase (BTK) inhibitor, transformed the therapeutic paradigm of B-cell malignancies upon its initial regulatory approvals. By forming a specific, irreversible covalent bond with the Cysteine 481 (Cys481) residue near the ATP-binding pocket of the BTK enzyme, Ibrutinib effectively disrupts downstream B-cell receptor (BCR) signaling networks. This inhibition prevents cellular proliferation, adhesion, migration, and survival in pathologically transformed lymphocytes.
Primary oncology applications include Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL), Waldenström’s Macroglobulinemia (WM), and Chronic Graft-versus-Host Disease (cGVHD).
With primary compound patents expiring across major markets globally between 2026 and 2030, OEM contract manufacturing demand is accelerating rapidly in emerging and semi-regulated markets.
OEM exporters must meet stringent WHO-GMP, US-FDA, and EU-GMP standard limits for genotoxic impurities, crystal polymorphism consistency, and particle size distribution (PSD).
The transition of BTK inhibitor therapies from innovator monopolies to localized generic formulations requires robust CDMO supply chains. Strategic OEM partners offering fully integrated API synthesis, crystalline form stability (Form I vs Form II), and bioequivalent finished dosage forms (FDF) enable generic drug sponsors to reduce time-to-market by up to 24 months while maintaining full regulatory compliance.
In-depth technical specifications of OEM Ibrutinib API production, route optimization, and crystalline integrity.
Commercial synthesis of high-purity Ibrutinib requires precise control over multi-step organic reaction pathways to prevent the accumulation of regioisomeric and stereoisomeric impurities. The synthesis typically originates from 4-phenoxybenzoyl chloride reacting with malononitrile, followed by condensation with hydrazine derivatives to form the pyrazolo[3,4-d]pyrimidine core scaffold.
| Test Parameter | Specification Limit | Analytical Method | Strategic OEM Impact |
|---|---|---|---|
| Chemical Name | 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one | IUPAC Nomenclature | Structural Verification |
| Assay Purity (HPLC) | 99.5% - 100.5% (Dry Basis) | HPLC-UV / Reverse Phase | Maximizes Therapeutic Potency |
| Chiral Purity (S-Enantiomer) | ≤ 0.10% | Chiral HPLC | Ensures Target Selectivity |
| Polymorphic Form | Form A / Form I (Stable Crystalline) | X-Ray Powder Diffraction (XRPD) | Guarantees Dissolution Stability |
| Particle Size Distribution | d(0.9) < 10 µm (Micronized Grade) | Laser Diffraction (Malvern) | Optimizes Bioavailability & Content Uniformity |
| Genotoxic Impurities | Below Threshold of Toxicological Concern (TTC) | LC-MS/MS | Satisfies ICH M7 Safety Guidelines |
Ibrutinib exhibits several polymorphic forms, of which anhydrous Form A is the most thermodynamically stable form under ambient storage conditions. Deviations in crystallization temperature, solvent moisture, or cooling rates during API isolation can induce conversion into metastable amorphous phases or solvates, leading to erratic dissolution profiles in oral capsule and tablet products. Professional OEM suppliers enforce continuous crystallization monitoring (FBRM/PVM technology) paired with air-jet micronization to achieve consistent particle sizes suitable for immediate-release solid dosages.
Navigating regional registration, tech transfers, and clinical supply chains across international markets.
Enabling local pharmaceutical importers in Brazil (ANVISA), Mexico (COFEPRIS), and Southeast Asia to file fast-track oncology dossiers via fully compiled eCTD Module 3 drug master files.
Custom formulation capabilities including 70mg, 140mg Hard Gelatin Capsules and 140mg, 280mg, 420mg, 560mg Film-Coated Tablets tailored to localized hospital tender requirements.
Zone IVb (30°C / 75% RH) stability-tested packaging solutions (Alu-Alu blisters, HDPE bottles with desiccant) preventing moisture-induced degradation during tropical international transit.
From chemical synthesis to global commercialization: How Gentolex powers the oncology supply chain.
Navigating the complex oncology market requires more than simple raw material supply. Commercial buyers, generic formulation developers, and institutional distributors require integrated partners capable of providing complete technology transfer, analytical validation, and regulatory protection.
Scalable synthesis from multi-kilogram pilot batches to multi-ton commercial API scale, utilizing advanced high-potency containment systems (OEL Class 4).
Excipient compatibility optimization and comparative dissolution profiling against innovator products (Imbruvica®) to guarantee invivo bioequivalence.
Complete Freedom-to-Operate (FTO) patent landscape analysis and full CTD dossier licensing out for rapid registration in target jurisdictions.
Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide.
Advanced process development, scale-up synthesis, bioanalytical validation, and formulation R&D tailored for modern oncology and peptide therapeutics.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
View Details
Addressing critical technical, regulatory, and logistics queries for international pharmaceutical buyers.
Stay updated with our technical breakthroughs and global pharmaceutical supply announcements.
Introduction to Selank Acetate API Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient (API) composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)...
View Details
Trusted Thymosin Beta-4 API Manufacturer and Global Peptide Supplier As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions...
View Details
Introduction BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair...
View Details
With the continuous development of neuroscience, peptide technology, and life science research, neuroactive peptides have become an important area of scientific investigation...
View Details
SS-31 (Elamipretide) API SS-31 API, also known as Elamipretide, MTP-131, Bendavia, and SS31, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin...
View Details
High-purity fine chemicals and custom batch manufacturing solutions.
